Marker Therapeutics Inc (MRKR)

[Phantom Lord]

If they are going to run any combination trial the checkpoint inhibitors make a lot sense. For a while it seemed like Merck was providing Keytruda to any small bio that wanted to run a combo trial. Issue being they were just providing Keytruda and no additional resources so it was still on the other company to fund the trial. Right now Marker does not have the funds to run another trial so without additional financial backing it's going to be a tough task. They're running bare bones right now, or at least should be (we'll find out in a couple of weeks), just to get to some major inflection points before they run out of cash and hopefully with no more dilution until we get a substantial increase in share price.

On a separate note, I received some additional clarification on the clinical review delay. We all know that they received ~$17M in grant money from different entities. Since they are basically restructuring their trials they are wanting to run everything by those entities as to not put the grant money in jeopardy before they present the review. Take this for what it's worth as they already made it sound like we should have had this review by now.